Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/6223
Title: | Aripiprazole in delusional disorder | Authors: | Duvar, H. Şengül, Cem Herken, Hasan |
Keywords: | Aripiprazole Delusional disorder Treatment aripiprazole olanzapine risperidone sertraline venlafaxine adult article blood cell count case report computer assisted tomography delusional disorder drug dose titration drug efficacy drug withdrawal extrapyramidal symptom female human major depression nuclear magnetic resonance imaging patient compliance prognosis psychomotor retardation rigidity side effect tremor unspecified side effect weight gain |
Abstract: | Though it has been known for a long time, due to the fact that the controlled studies are limited and the disorder is uncommon, case reports have been important supporting the data of the treatments. In general, depending on whether the patient used drug before and considering the effects and side effects of the drugs the first choice in the treatment is antipsychotic drugs. New atypical antipsychotic agents are preferred for their relatively less side effects and higher drug adaptation. We aimed to report a case of delusional disorder (jealous type) which did not respond to different atypical antipsychotic agents previously but shows a prognostic improvement by aripiprazole of 30mg/day. Aripiprazole may be an effective option for the treatment of delusional disorder, with few side effects, high drug compliance and efficacy. | URI: | https://hdl.handle.net/11499/6223 | ISSN: | 1304-3889 |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
Files in This Item:
File | Size | Format | |
---|---|---|---|
aripiprazole-in-delusional-disorder-6822.pdf | 263.04 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
5
checked on Nov 16, 2024
Page view(s)
44
checked on Aug 24, 2024
Download(s)
22
checked on Aug 24, 2024
Google ScholarTM
Check
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.